PNC Financial Services Group Inc. Sells 1,367 Shares of Immunomedics, Inc. (NASDAQ:IMMU)

PNC Financial Services Group Inc. decreased its stake in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 23.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,583 shares of the biopharmaceutical company’s stock after selling 1,367 shares during the period. PNC Financial Services Group Inc.’s holdings in Immunomedics were worth $65,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of IMMU. Exane Derivatives bought a new stake in Immunomedics during the 4th quarter worth approximately $32,000. North Star Investment Management Corp. bought a new stake in Immunomedics during the 4th quarter worth approximately $50,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Immunomedics by 16.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,151 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 1,140 shares in the last quarter. Union Bankshares Corp bought a new stake in Immunomedics during the 4th quarter worth approximately $143,000. Finally, Exencial Wealth Advisors LLC bought a new stake in Immunomedics during the 4th quarter worth approximately $217,000. Institutional investors and hedge funds own 85.22% of the company’s stock.

A number of analysts recently issued reports on IMMU shares. Jefferies Financial Group set a $30.00 target price on Immunomedics and gave the stock a “buy” rating in a research note on Sunday, December 23rd. B. Riley initiated coverage on Immunomedics in a research note on Tuesday, January 8th. They set a “buy” rating and a $55.00 target price for the company. Zacks Investment Research raised Immunomedics from a “sell” rating to a “hold” rating in a research report on Thursday, January 10th. BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. Finally, Wells Fargo & Co downgraded Immunomedics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $44.00 to $18.00 in a research report on Friday, January 18th. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.45.

Shares of NASDAQ IMMU traded up $0.34 during trading hours on Friday, hitting $16.99. The company had a trading volume of 3,228,026 shares, compared to its average volume of 2,290,557. Immunomedics, Inc. has a 1-year low of $11.55 and a 1-year high of $27.33. The company has a market cap of $3.24 billion, a PE ratio of -16.50 and a beta of 2.11. The company has a current ratio of 13.45, a quick ratio of 13.45 and a debt-to-equity ratio of 0.06.

Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings results on Monday, February 25th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.16). As a group, sell-side analysts predict that Immunomedics, Inc. will post -1.38 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “PNC Financial Services Group Inc. Sells 1,367 Shares of Immunomedics, Inc. (NASDAQ:IMMU)” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/pnc-financial-services-group-inc-sells-1367-shares-of-immunomedics-inc-immu.html.

Immunomedics Company Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Read More: Investing in Dividend Stocks

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.